DALE GENE BRAMLET, MD CPI

CURRICULUM VITAE

Clinical ResearchPractice Phase II& III

Ascension Research, LLC4820 Park BoulevardPinellas Park, FL 33781Phone: (727) 521-9200 Ext. 307 Fax: (727) 231-8000dbramlet@adventcrc.comCell Phone 727-276-2858

Clinical ResearchOrganization

ReEval LLC4820 Park Blvd Pinellas Park, FL 33781-3534727-521-9200 Ext 311 Fax: 727-231-8000

EDUCATION

Undergraduate 8/73 - 8/77 Bachelor of Arts, ChemistryBachelor of Science - Presidents DegreeDiversified Sciences, Southern Illinois University, Carbondale, IL

Graduate 8/77 - 6/79 Master of Science in PhysiologySouthern Illinois University, Carbondale, IL

Medical 6/79 - 6/82 M.D. Southern Illinois University, School of Medicine801 N. Rutledge, Springfield IL

Postgraduate 6/82 - 6/83 Internship: Flexible Surgery Oregon Health Sciences University 3181 S.W. Sam Jackson Park RoadPortland, OR 97201

7/83 - 7/87 Residency: OrthopaedicSurgery Oregon Health Sciences University 3181 S.W. Sam Jackson Park RoadPortland, OR 97201

7/87 - 6/88 Fellowship: Instructor in Orthopaedic and Plastic Hand SurgeryUniversity of Rochester601 Elmwood Avenue, Rochester, NY 14642

1

UniversityResearch

Graduate Thesis: The Role of Serotonergic Neurons in the Development and Maintenance of Hypertension in the Spontaneously Hyperactive Rat. Teaching Assistantship: Department of Physiology Southern IL University 1978 – 1979

Work History Private Practice 8/1/88 - 10/1/896350 Central Avenue, St. Petersburg, FL 33707 Group Practice 10/89 to 2010President, All Florida Orthopaedic Associates4600 Fourth St No., St. Petersburg, FL 337031995 to 2010 - Director of Research Vested member in a 16 physician firmMarch 29th 2010 – November 2012 Share a practice location with Dr. Thomas Tolli MD and Dr. David Rubins MD

November 2012 – Augsut, 2015 Dale G. Bramlet MD PL and Advent Orthopaedics and Rehabilitation LLC – Retired August 10 th , 20154820 Park Bvd, Pinellas Park, FL 33781727-544-0320 Fax: 727-209-6693

CEO Ascension Research LLC August 2017 – CurrentCEO ReEval LLC CRO 2018CEO Advent Medical Research Inc 2006 - 2017Advent Clinical Research Centers (2002 – 2017),All Florida Center for Clinical Research 1995 - 2009

State Licensure: Florida April 1988 ActiveNew York April 198 (inactive)Oregon July 1983 (inactive)

Boards and Fellowships

1983 Diplomat National Board of Medical Examiners 1990 Diplomat American Board of Orthopaedic Surgeons1992 Diplomat ABOS, Hand Surgery1992 - Present Fellow American Academy of Orthopaedic Surgeons2001- 2010 Re-Certification American Board of Orthopaedic Surgeons2001 - 2010 Re-Certification ABOS, Hand Surgery2010 - 2020 Re-Certification American Board of Orthopaedic Surgeons2010 - 2020 Re-Certification ABOS, Hand Surgery2003 - Present CPI Certification #03-S004 Certified Principal Investigator, ACRP

Professional Societies

1982 -2015 American Medical Association1983 - 1987 Oregon State Medical Society

2

1983 - 1987 Multnomah County Medical Society1983 - 1987 Western Orthopaedic Association OR Chapter1988 - Present Pinellas County Medical Society1988 - Present Florida Medical Association1990 - Present Southern Orthopaedic Association1990 - Present Florida Hand Society1990 - Present Florida Orthopedic SocietyInducted 2/92 American Academy of Orthopaedic SurgeonsInducted 9/93 American Society for Surgery of the Hand2002 - Present Drug Investigators Association2002 - Present Association of Clinical Research Professionals2003 - Present CPI Certification #03-S004 Principal Investigator, ACRP2003 - Present Association of Physician and Pharmaceutical Investigators1983 ACLS and ATLS Certified2008 – 2014 t Certification in ACLS

Hospital Privilege List

Hospitals Current Status Effective DateAll Children’s Hospital Inactive 08/88 - 2016Bayfront Medical Center Inactive 09/88 - 2010Edward White Hospital Closed 10/88 - 2013Largo Medical Center Inactive 06/11 - 2015Northside Hospital Inactive 11/88 - 2015Palms of Pasadena Hospital Inactive 08/88 - 2015St. Anthony’s Hospital Inactive 09/88 - 2015St. Petersburg General Inactive 04/92 - 2015Surgery CentersBayfront Medical Plaza Inactive 1/95 - 12, 2012Center for Special Surgery Inactive 10/95 - 2015

Business Background

2017 – Present CEO, Advent Research LLC

2006 - 2017 Founder and CEO, Advent Medical Research Inc and numerous subsidiaries

2002 - 2017 Founder and CEO - Advent Clinical Research Centers, Inc. dba Advent Research

2010 - Present President of Dale G. Bramlet MD LLC, a limited liability corporation for Dr. Bramlet‘s Medical Practice in Conjunction withAdvent Orthopaedics and Rehabilitation LLC

2008 – Present President and Founder, Ascension Research LLC

3

2018 – Present President, Hope Wellness Center LLC

2018 - Present CEO, ReEval LLC, CRO

2012 - 2017 President, Advent Orthopaedics and Rehabilitation, LLC

2006 - 2014 President, Sarasota Research LLC

2007 - Present President and Founder of Mid-County 1 LLC, a Real Estate LLC

2000 - 2010 Director Clinical Research, All Florida Orthopaedic Associates

1999 - 2011 Vice President Big Game Sports Inc., A Florida Corporation for Real Estate Development of Commercial Buildings

1998 - 2009 President/Director, All Florida Orthopaedic Associates, A group of sixteen physicians and staff providing Orthopaedic care and therapy

1995 - 2009 Vice President Forty Sixth Avenue Development Corporation, a Florida Real Estate Holding Corporation

1995 - 2009 Founder and Chairman of the Board of Orthopedic Designs, Inc., Active in implant design with ten US patents issued and five FDA allowed products. These patents cover approximately ten product lines.

2009 - 2010 Chairman of the Board, Orthopedic Designs, Inc., North America

1995 - 2009 Chairman of the Governing Body of Center for Special Surgery, Active in development of 9,000 sq. ft Ambulatory Surgery Center, which opened February 1996. Medical Executive Committee from 1995 to 2009

1995 - 2000 Officer of BDW Properties, Inc., a Florida Real Estate Holding Corporation

1993 - 1996 Vice President First Florida Medical, Participated in acquiring control of a distressed local hospital, Physicians Community Hospital, which was then sold to a national firm specializing in acute, long-term care facility development.

1992 - 2009 Vice President Fourth Street Development Corporation, a Florida

Real Estate Holding Corporation

4

1991 - 2009 Corporate Secretary/Board of Directors, All Florida Orthopaedic Associates

Community Involvement

1996 - 2011 Member of the Board of Directors, St. Petersburg Junior College Development Foundation, Inc.

1988 - 2007 Attend First United Methodist Church

2nd Ave North, St. Petersburg, FL 33701

1998 - 2004 Mission Coordinator for Faith in Practice yearly mission to Antigua, Guatemala to provide volunteer surgical services and Active in First Presbyterian Church, St. Petersburg, Florida

2011 - Present International Missions Council, Kenya Missions, First United Methodist Church, St. Petersburg, Florida

2011 - 2013 Physician Advisor, Keiser Career College (Southeastern College) Surgical Assistant Program

Appointments

1990 - 1992 Section Chief of Hand SurgeryBayfront Medical Center, St. Petersburg FL

1992 - 2002 Section Chief of Orthopaedics

St. Anthony's Hospital, St. Petersburg, FL 1992 - 2002 Section Chief of Hand Surgery

St. Anthony's Hospital, St. Petersburg, FL

1992 - 2009 Clinical Assistant Professor

Department of Family MedicineUniversity of South Florida, Tampa FL

1990 - 1992 Medical Council

Palms of Pasadena Hospital, St. Petersburg, FL

1991 - 1994 Quality Assurance Department of SurgeryBayfront Medical Center, St. Petersburg, FL

1992 - 1993 Emergency Room Committee

St. Anthony's Hospital, St. Petersburg, FL 1993 - 1995 Board of Directors

Physician's Community Hospital, St. Petersburg, FL

5

1995 - 2009 Chairman of the Governing Body of Columbia Center for Special

Surgery, later renamed Center for Special Surgery. Active in development with Columbia HCA of 9,000 sq. ft Ambulatory Surgery Center, which opened February 1996.

1995 - 2009 Executive Committee, Center for Special Surgery, 4650 4th St. North, St. Petersburg, Fl 33703

2001 - 2007 Medical Director, Hand Trauma Program, Bayfront Medical

Center, St. Petersburg, FL

2011 - 2012 Director, Total Joint Reconstruction Program, Edward White Hospital

6

Scientific Research

1. Principal Investigator for St. Petersburg area for Sanofi Winthrop Clinical Trial DRI2643a Multicenter, Randomized, Parallel, Double Blind, Dose Ranging Study ofSubcutaneous XXXX with an Assessor Blind, Comparative Control Group ofSubcutaneous XXXX in the Prevention of Deep Vein Thrombosis after Elective Total HipReplacement -1997

2. Principal Investigator for St. Petersburg area for Sanofi Clinical Trial EFC2442 AMulticenter, Multinational, Randomized, Double-blind Comparison of SubcutaneousXXXX with XXXX in the Prevention of Deep Vein Thrombosis and SymptomaticPulmonary Embolism after Elective Hip Replacement -1998/1999

3. Principal Investigator for St. Petersburg area for Organon Clinical Trial Phase IIIPentasaccharide Program for DVT Prophylaxis. A Multicenter, Multinational,Randomized, Double-blind Comparison of Subcutaneous XXXX with SubcutaneousXXXX in the Prevention of Deep Vein Thrombosis and Symptomatic PulmonaryEmbolism in Subjects Undergoing Total Knee Replacement Surgery -1998/1999

4. Biomechanical Evaluation of a Hip Screw System with Retractable Tangs, with DonnaWheeler, PhD, University of Florida, Department of Orthopaedics, Gainesville, FL -1999

5. Biomechanical Comparative Analysis of an Unstable 4-Part Intertrochanteric FractureFixed by Two Compressive Hip Fixation Devices, University of Miami OrthopedicBiomechanical Lab, Miami Beach FL, May 2000 with Edward L. Milne Technical Director andLoren L. Latté, Director

6. Principal Investigator for St. Petersburg area for Orthologic Clinical Trial #OL10-99-01,A Prospective, Double-Blind, Randomized, Placebo-Controlled Phase I/II to Evaluate theSafety of XXXX and the Effect of XXXX on the Rate of Healing in Distal RadiusFractures -2000

7. Principal Investigator for St. Petersburg area for Searle/Pfizer Clinical Protocol forSuccessive XXXX Efficacy and Safety Studies. A Multicenter, Double-Blind, Placebo-Controlled, Randomized, Parallel Group Study in the U.S. to Compare the Efficacy andTolerability of XXXX vs. Ibuprofen in Ankle Sprains (SUCCESS-IIA) IND #48,395-1999 - 2000

8. Principal Investigator for St. Petersburg area for Astra Zeneca Protocol 237, ARandomized, Double Blind, Comparative Study of XXXX and XXXX for the Prevention ofVenous Thromboembolism Following Total Hip Arthroplasty. -2000 - 2001

9. Consultant for National Institutes of Health Phase I Study Entitled: High Toughness HighImpact Resistant Hip Implants. -2001

10. Principal Investigator for St. Petersburg area for Astra Zeneca Protocol 290, [EXULT]KNEE: Optimization of Dose (Study A) and Confirmation of Safety and Efficacy (Study

7

B) of XXXX (Oral Direct Thrombin Inhibitor) Compared to XXXX (XXXX) for thePrevention of Venous Thromboembolism Following Total Knee Arthroplasty (TKA)-2001

11. Principal Investigator for St. Petersburg area for Glaxo Smith Kline Protocol SB424323for Thromboembolism Prevention Efficacy and Safety Trial (TEMPEST): A Double-blindFour-week Study to Assess the Efficacy, Safety, and Tolerability of XXXX in theExtended Prophylaxis Following Total Hip Arthroplasty -2001 - 2002

12. Principal Investigator for St. Petersburg area for Pharmacia Corporation Protocol 524E-CVD-0042-029 Thromboprophylaxis with Low Molecular Weight XXXX vs. XXXX inPatients Undergoing Primary Total Knee Replacement A Multi-center, Prospective,Randomized, Open-Label Study. -2001 - 2002

13. Principal Investigator for St. Petersburg area for Amgen, Inc. Protocol #20010117 ADouble-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safetyof Subcutaneous (SC) XXXX XXXX in Subjects Undergoing Preoperative AutologousBlood Donation (PAD) Before Elective Revision Total Hip Replacement or BilateralKnee Replacement Surgery -2001 - 2002

14. Principal Investigator for St. Petersburg area for Merck Protocol 061-00/COX523. Arandomized, Double-Blind, Multicenter Study to Evaluate the Tolerability andEffectiveness of XXXX 90 mg qd vs. XXXX 50 mg tid in Patients with Osteoarthritis-2002

15. Principal Investigator for St. Petersburg area for Amgen, Inc. Protocol #20010181 AnOpen label, Parallel-Group Study to Assess Safety in Subjects Receiving a Single-Subcutaneous (SC) Dose of XXXX XXXX or Undergoing Preoperative AutologousDonation (PAD) Before Elective Noncardiac, Nonvascular Surgery -2002

16. Principal Investigator for St. Petersburg area for Orthologic Clinical Trial #OL09-01-03,A Double-Blind, Randomized, Placebo-Controlled Phase III Study to Evaluate theEfficacy and Safety of XXXX on the Rate of Healing in Distal Radius Fractures -2002

17. Principal Investigator for Merck, Inc., Protocol 072-00 A Randomized, Double-BlindMulticenter Study to Evaluate the Tolerability and Effectiveness of XXXX 90 mg Q.D.Versus XXXX XXXX 75 mg B.I.D. in Patients with Rheumatoid Arthritis -2003

18. Principal Investigator for St. Petersburg area for PRA/Organon/Sanofi/SynthelaboProtocol L8518 “Flexibility in Administration of Arixtra for Prevention of SymptomaticVenous Thromboembolism in Orthopaedic Surgery” -2003

19. Principal Investigator for St. Petersburg area for Ortho Biotech, An Open-LabelRandomized, Parallel-Group Study to Confirm the Safety and Efficiency of XXXX(XXXX) Administered Perioperatively vs. the Standard of Care in Blood Conservation inSubjects Undergoing Major Spinal Surgery -2003

8

20. MO3-644 Phase III, Randomized, Double-Blind, Fixed Dose, Parallel-Group,Comparison of Controlled-Release XXXXXXXX (XXX) vs. Placebo in Subjects withOsteoarthritis -2003

21. Principal Investigator for St. Petersburg area for Clinical Trial OL10-01-01. AProspective, Randomized, Controlled Phase I/II Study to Evaluate the Safety andEfficiency of XXXX on Bone Healing in Lumbar Spinal Fusion -2003

22. Principal Investigator for St. Petersburg Area for Clinical Trial 10945. Oral direct factorXXXX inhibitor XXXX in the prevention of VTE inpatient undergoing total kneereplacement -2003

23. Principal Investigator for St. Petersburg area for Clinical trial ABT713 A Phase III,Randomized, Double-Blind, Fixed-dose Parallel-Group Comparison of Controlled-Release XXXXXXX vs. Placebo I Subjects with Osteoarthritis -2004

24. Principal Investigator for St. Petersburg area for Clinical TrialA3471109. A Multicenter,Double-Blind, Placebo-Controlled Randomized study of the Analgesic Efficacy andSafety of XXXX 20mg QD and XXXX 20mg BID. Compared to Placebo Over MultipleDays for Management of Acute Postsurgical Pain in Patients Undergoing AnteriorCruciate Ligament Reconstruction -2004

25. Principal Investigator for St. Petersburg area for Clinical TrialOL10-01-01 A Prospective,Randomized, Controlled Phase I/II Study to Evaluate the Safety and Efficacy of XXXXon Bone Healing in Lumbar Spinal Fusion -2004

26. #CV185-010 A Phase II Randomized, Double-Blinded (XXXX)and XXXX), Active-Controlled (XXXX and XXXX),Parallel-Arm, Dose-Response Study of the Oral FactorXaInhibitor BMS-562247 in Subjects undergoing Elective Total Knee ReplacementSurgery -2004

27. #OL-Adrfx-03 A Double Blind, Randomized, Placebo-controlled Phase IIb Study toEstablish the Effective Dose Range and to Evaluate the Safety of XXXX in AdultSubjects with a Fractured Distal Radius -2004.

28. #3100N7-109-US A Phase I, Dose Escalating, Open Label, Safety and Feasibility Studyof Recombinant Human Bone XXXXXXXX (XXXX) Calcium Phosphate Matrix (CPM)as an Adjuvant Therapy for Closed Femoral Diaphyseal Fractures Treated with ReamedStatically Locked Antegrade or Retrograde Intramedullary (IM0 Nail Fixation -2004

29. #1160.24 A Phase III Randomized, Parallel-Group, Double-Blind, Active ControlledStudy to Investigate the Efficacy and Safety of Two Different Dose Regimens (75mg Day1 followed by150mg Day 2- Completion, and 110 mg Day 1 Followed by 22mg Day2Completion) of XXXX XXXX Administered Orally (Capsules), Compared to XXXX30mg Twice a Day Subcutaneous For 12-15 Days, in Prevention of Venous Thrombolismin Patients with Primary Elective Total Knee Replacement Surgery (Re-Mobilize) -2004

9

30. DU176b-PRT007 A Phase IIa, Multi-Center, Multi-National, Open-Label, Dose RangingStudy of the Efficacy, Safety, and Toler-Ability of Oral XXXX Administered Once toTwice Daily in the Treatment of Adult Patients Undergoing Total Hip Arthroplasty -2004.

31. A Multi-Center Double-Blind, Placebo-Controlled Randomized Study of XXXX 200mgBID, XXXX 300mg BID, and XXXX 400mg BID in the Treatment of Chronic Low BackPain -2004

32. A Multicenter, Double-Blind, Placebo-Controlled, Randomized Study of the AnalgesicEfficacy and Safety of XXXX 20mg QDand XXXX 20BID Compared to Placebo OverMultiple Days for Management of Acute Postsurgical Pain in Patients UndergoingAnterior Cruciate Ligament (ACL) Reconstruction -2004

33. BAY a 0128/11694: A Multi-Center, Randomized, Double-Blind, Placebo-Controlled,Parallel Design, 2-Arm Study to Investigate the Effect of XXXX on TransfusionRequirements and Blood Loss in Patients Undergoing Elective Primary Total HipReplacement Surgery -2004

34. Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety,Tolerability and Pharmacokinetics of XXXX, XXXX in Subjects with Closed Fracture ofthe Tibial Shaft -2005

35. A 13 Week, Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel Group Trial of XXXX(XXXX) 100mg O.D, in Patients with PrimaryHip Osteoarthritis using XXXX (200mg O.D.) as a Positive Control - 2005

36. A Multi-Center, Randomized, Placebo-Controlled, Phase III Efficacy and Safety Study ofXXXX in Patients with Moderate to Severe Chronic Pain due to Osteoarthritis of the Hipor Knee

37. Protocol: 3040 An Open-Label, 12 Month Study to Evaluate the Safety, Tolerability, andEfficacy of XXXX XXXXXXXX for the Management of Breakthrough Pain in Opioid-Tolerant Patients with Chronic Noncancerous Pain -2005

38. SK SB767905/012: A Randomized, Double-Blind, Placebo-Controlled, Multicenter PhaseIII Study to Evaluate the Efficacy and Safety of XXXX 0.5mg Once Daily and 0.5mgTwice Daily for 12 Weeks for the Treatment of Opioid-Induced Bowel Dysfunction inAdults taking Opioid Therapy for Persistent Non-Cancer Pain -2005

39. GSK SB767905/014: A Randomized, Double-Blind, Placebo- Controlled, MulticenterPhase III Study to Evaluate the Long-Term Safety of XXXX 0.5mg Twice Daily for 12Months for the Treatment of Opioid-Induced Bowel Dysfunction in Adults taking OpioidTherapy for Persistent Non-Cancer Pain -2005

40. GSK ITI101711: A Dose Ranging Trial for the Evaluation of the Safety, Tolerability and

10

Efficacy of XXXX in the Prevention of Venous Thromboembolism following Total KneeReplacement Surgery -2005

41. Principal Investigator for Protocol 17CL228, A Phase II, Multicenter, Double-Blind,Placebo-Controlled, Dose-Ranging, Parallel-Group Study of XXXX for the Prevention orReduction of Opioid-Induced Gastrointestinal Side Effects in Subjects Undergoing AmbulatoryShoulder Surgery -2006

42. Principal Investigator for Protocol HM2006001, Multi-Center XXXX SkinIrritation/Sensitization Pilot Study in Non-Opioid-Naïve Patients -2006

43. Principal Investigator for Protocol M04-697, A Phase III, Randomized, Multicenter,Double-Blind Study Comparing the Analgesic Efficacy of Extended Release XXXX/XXXXTablets XXXX to Placebo in Subjects with Osteoarthritis -2006

44. Principal Investigator for Protocol A55710/1038, A Phase IIb, Randomized, Multicenter,Dose-Ranging Study Assessing the Safety and Efficacy of XXXX in the Prevention of VenousThromboembolic Events (VTE) in Subjects Undergoing an Elective, Unilateral Total KneeReplacement -2006

45. Principal Investigator for Protocol 3100N7-210-WW, A Phase II/III Multicenter, Double-Blind, Randomized, Controlled Study of Recombinant Human Bone Morphogenetic Protein-2(rhBMP2)/Calcium Phosphate Matrix (CPM) in closed Diaphyseal Tibial Fractures -2006

46. Principal Investigator for Protocol 3100N7-211-WW, A Phase II, Multicenter, Single-Blind, Randomized, Stratified, Standard of Care Controlled, Feasibility and Safety Study ofrhBMP-2-CPM as an Adjuvant Therapy for Fractures of the Proximal Femur -2006

47. Principal Investigator for Protocol 3100N7-212-WW, A Phase II, Multicenter, Double-Blind, Randomized, Stratified, Controlled, Efficacy, Safety and Feasibility Study of rhBMP-2/CPM as an Adjuvant Therapy in Closed Fractures of the Humerus -2006

48. Principal Investigator for Protocol 11355, Regulation of Coagulation in OrthopedicSurgery to Prevent DVT and PE; a controlled, double-blind, randomized study of XXXX in theprevention of VTE in subjects undergoing elective total knee replacement -2006

49. Principal Investigator for Protocol A3241008-1013, A One-Year Follow-up Assessmentof Subjects who Participated in Protocol A3241002 -2006

50. Principal Investigator for Protocol SMI05002, Survey to assess the prevalence,characteristics and impact of breakthrough pain in chronic pain patients with and without cancermanaged by clinicians who are not pain specialists -2006

51. Principal Investigator for Protocol DU176b-PRT011, A Phase IIb, Randomized, ParallelGroup, Double-Blind, Double-Dummy, Multi-Center, Multi-National, Multi-Dose Study of XXXCompared to XXX in Patients Undergoing Elective Unilateral Total Hip Replacement -2006

11

52. Principal Investigator for Protocol C25608/3040/BP/US, An Open-Label, 12-monthStudy to Evaluate the Safety, Tolerability, and Efficacy or XXXX XXXXXXXX for theManagement of Breakthrough Pain in Opioid-Tolerant Patients with Chronic Noncancerous Pain- 6 month extension study -2006

53. Principal Investigator for Protocol 2005-01D, A Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of XXXXX for Treatment of Painful Osteoarthritisof the Knee, with an Open-Label Safety Extension, 2006

54. Principal Investigator for Protocol 2006-02, A Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of XXXXX for Treatment of Osteoarthritis (OA) ofthe First Carpometacarpal (CMC) Joint

55. A3191331, Gastrointestinal (GI) Randomized event and safety open label NSAID study(GI-REASONS) A randomized, open-label, blinded-endpoint, parallel-group trial of GIsafety of XXXX compared with non-selective nonsteroidal anti-inflammatory drugs(NSAIDS) in osteoarthritis patients. -2007

56. Principal Investigator for Protocol 150-CL-033, A Phase IIb, Double Blind, Double-Dummy, Randomized, Parallel Group Study to Evaluate the Safety and Efficacy of TwiceDaily Dosing and Once Daily Dosing of XXXX In Subjects Undergoing Primary ElectiveKneeArthroplasty -2008

57. Protocol WA2049A/ACT3985g, A Randomized, Double-Blind, Parallel Group, International Study to Evaluate the Safety and Efficacy of XXXX Compared Placebo in Patients with Active Rheumatoid Arthritis Continuing Methotrexate Treatment

58. Protocol WA20496/ACT4394g, A Randomized, Double-Blind, Parallel Group, International Study to Evaluate the Safety and Efficacy of XXXX Given as a Single Infusion of Dual Infusion Compared with Placebo in Patients with Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate Therapy

59. Protocol KF5503/16: R331333-PAI-3014, A Randomized Withdrawal, Active and Placebo-Controlled, Double-Blind, Multicenter Phase III Trial Assessing Safety and Efficacy of Oral XXXX in Subjects with Moderate to Severe Chronic Malignant Tumor-Related Pain -2007

60. Principal Investigator Protocol NMT 1077-301, A Phase III, Variable-Dose Titration Followed by a Randomized Double-Blind Study of Controlled-Release XXXX Comparedto Placebo in Patients with Chronic Low Back Pain -2008

61. Principal Investigator Protocol NMT 1077-302, A Phase III, Flexible-Dose Titration Followed by a Randomized Double-Blind Study of Controlled-Release XXXX Comparedto Placebo in Patients with Osteoarthritis Pain -2007

12

62. Protocol C0407 Multicenter, Open Label Extension Study of 8 mg XXXX in Subjects who completed Protocols C0405 or C0406 for Symptomatic Gout -2007

63. Protocol 01-06-TL-OPIMET-008, A Phase IIIb, Double-Blind, Randomized Study to Determine the Efficacy and Safety of XXXX and XXXX Fixed-Dose Combination Therapy Compared to XXXX and to XXXX in the Treatment of Subjects with Type 2 Diabetes -2007

64. Principal Investigator Protocol TAK-442_201, A Phase II, Randomized, Active Comparator-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of XXXX in Subjects Undergoing Total Knee Replacement -2007

65. Principal Investigator Protocol 11355 BAYER RECORD 4 Study: Regulation of Coagulation in Orthopedic Surgery to Prevent DVT and PE; a Controlled, Double-Blind, Randomized Study of XXXX in the Prevention of VTE in Subjects Undergoing Elective Total Knee Replacement -2006

66. Protocol NU281, Effects of the Consumption of Plant Sterols-enriched Dairy Fermented Product on Hypercholesterolemia Management in Hypercholesterolemic Adults -2008

67. Principal Investigator Protocol 150-CL-033 A Phase IIb, Double-Blind, Double-Dummy, Randomized, Parallel Group Study to Evaluate the Safety and Efficacy of Twice Daily Dosing and Once Daily Dosing of XXXX in Subjects Undergoing Primary Elective KneeArthroplasty -2007

68. Sub-Investigator Protocol 150-CL-033, A Phase IIb, Double-Blind, Double-Dummy, Randomized, Parallel group Study to Evaluate the Safety and Efficacy of Twice Daily Dosing and Once Daily Dosing of XXXX in Subjects Undergoing Primary Elective KneeArthroplasty -2007

69. Principal Investigator Protocol 150-CL-040, A Randomized, Double-Blind, Double-Dummy, Parallel Group Study to Compare XXXX bid and qd Doses and XXXX for Prevention of Venous Thromboembolism in Subjects Undergoing Elective Hip Replacement Surgery -2009

70. Principal Investigator Protocol A4091011, A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of the Analgesic Efficacy and Safety of XXXX in Patients with Osteoarthritis of the Knee -2008

71. Principal Investigator Protocol A4091012, A Phase III, Randomized, Double-Blind, Multidose, Active and Placebo Controlled, Multicenter, Parallel Group Study of the Analgesic Effects of XXXX in Adult Patients with Chronic Low Back Pain -2009

72. Principal Investigator Protocol A4091014, A Phase III, Randomized, Double-Blind, Placebo-controlled, Multicenter Study of the Analgesic Efficacy and Safety of XXXX in Patients with Osteoarthritis of the Hip -2008

73. Principal Investigator Protocol A4091016, A Phase III, Multicenter, Randomized, Long

13

Term Study of the Safety of XXXX in Patients with Osteoarthritis of the Knee of Hip -2009

74. Principal Investigator Protocol A4091025, A Phase III, Multicenter, Randomized, Double-Blind, Non-steroidal Anti-inflammatory Drug (XXXX)-Controlled Study of the Long Term Analgesic Efficacy and Safety of XXXX in Patients with Osteoarthritis of the Knee or Hip -2009

75. Principal Investigator Protocol A4091039, A Phase III, Randomized Double-Blind, Multidose, Active Controlled, Multicenter, Parallel Group Study of the Analgesic Effects of XXXX in Patients with Osteoarthritis of the Hip or Knee -2009

76. Principal Investigator Protocol EFC10571 (SAVE-KNEE), A Multinational, Multicenter, Randomized, Double-Blind Study Comparing the Efficacy and Safety of XXXX with XXXX for the Prevention of Venus Thromboembolism in Patients Undergoing Elective Knee Replacement Surgery -2009

77. Principal Investigator Protocol A4091040, A Phase III, Double-Blind, Placebo-Controlled, Multicenter, Long-Term Safety Study of XXXX in Patients with Osteoarthritis of the Knee or Hip

78. Principal Investigator Protocol EFC10342 (SAVE-HIP), A Multinational, Multicenter, Randomized, Double-Blind Study Comparing the Efficacy and Safety of AVE5026 with Enoxaparin in the Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Hip Replacement Surgery -2009

79. Sub-Investigator Protocol A4091003, A Phase II Randomized, Double-Blind, Placebo-Controlled Multicenter Efficacy and Safety Study of XXXX as Add-On Therapy to Opioid Medication in Patients with Pain Due To Bone Metastases -2009

80. Sub-Investigator Protocol A4091029, A Phase II Randomized, Double-Blind, Placebo-Controlled Multicenter Efficacy and Safety Study of XXXX as Add-On Therapy to Opioid Medication In Patients with Pain Due To Bone Metastases -2009

81. Principal Investigator Protocol ACT11308, A Randomized, Double-Blind, Placebo-Controlled Study of the Effect of a Single Injection of XXXX on Reduction of Pain FromVertebral Fracture Associated with Osteoporosis -2009

82. Principal Investigator Protocol ACT11286, A Randomized, Double-Blind, Placebo-Controlled Study of the Effect of a Single Injection of XXXX on Reduction of Pain from Chronic Pancreatitis -2009

83. Principal Investigator Protocol A4091026, A Phase III Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of XXXX on Peripheral Nerve Function in Patients with Osteoarthritis -2010

84. Sub-Investigator Protocol SP904, A Multicenter, Open-label Extension Trial to Asses the Long-term Use of XXXX and Safety of XXXX and Adjunctive Therapy in Subjects with

14

Partial-onset Seizures -2010

85. Sub-Investigator Protocol SP902, A Historical-controlled, Multicenter, Double-Blind, Randomized Trial to Assess the Efficacy and Safety of Conversion to XXXX Monotherapy in Subjects with Partial-onset Seizures -2010

86. Principal Investigator Protocol A4091040, A Phase III, Double-Blind, Placebo-Controlled, Multicenter, Long-Term Safety Study of XXXX in Patients with Osteoarthritis of the Knee or Hip -2010

87. Principal Investigator Protocol INCB 18424-351, A randomized, double-blind, placebo controlled study of the XXXX inhibitor XXXX tablets administrated orally to subjects with primary myelofibrosis (PMF) , post Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential ThrombocythemiaMyelofibrosis (PET-MF) -2010

88. Principal Investigator Protocol 102295, A Worldwide, Open Label, Clinical Trial to Examine the Long Term Safety and Tolerability of XXXX in Pediatric Migraineurs for the Treatment of Migraine with or without Aura -2010

89. Principal Investigator Protocol 0462-082-00, A Worldwide, Randomized, Double Blind, Placebo-Controlled, Parallel Group Clinical Trial to Evaluate the Safety and Efficacy of XXXX for the Acute Treatment of Migraine in Children and Adolescents -2010

90. Sub-Investigator Protocol CV185068, A Phase III, Randomized, Double Blind, Evaluation of the Safety and Efficacy of Apixaban in Subjects with a Recent Acute Coronary Syndrome

91. Sub-Investigator Protocol ALO-01-10-4033, A Multi-center, Primary Care-Based, Open-Label, Study to Assess the Success of Converting Opioid Experienced Patients, with Chronic, Moderate to Severe pain to EMBEDA™ Using a Standardized Conversion Guide, and to Identify Behaviors Related to Prescription Opioid Abuse, Misuse And Diversion -2010

92. Sub-Investigator Protocol 1218.75, A Phase IIIb, 24 week, Randomized, placebo-controlled, double-blinded, efficacy and safety study of XXXX in Black/African American patients With type 2 diabetes with a MTT sub-study -2010

93. Sub-Investigator Protocol SMR/0211OBD-1033, A Multicenter, Randomized, Placebo-controlled, Double-blinded Study of the Efficacy and Safety of XXXX in Subjects with Opioid-induced Bowel Dysfunction

94. Sub-Investigator Protocol WEL-A-U306 A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of Welchol® as Add-On to XXXX Therapy For Type 2 Diabetes Mellitus -2010

95. Principal Investigator Protocol 09-OA-002 A Phase II, Double-Blind, Randomized, Placebo-Controlled, Proof of Concept, Dose Finding Study of Intraarticular Bone Morphogenetic Protein (XXX) in Subjects with Osteoarthritis (OA) of the Knee -2010

15

96. Sub-Investigator Protocol H9B-MC-BCDM A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate The Efficacy and Safety of XXXX in Patients with Moderate to Severe Rheumatoid Arthritis (RA) who had an Inadequate Response To Methotrexate Therapy -2011

97. 100. Sub-Investigator Protocol H9B MC BCDO, A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate The Safety and Efficacy of XXXX inPatients with Rheumatoid Arthritis (RA) with or without Background Disease-Modifying Anti-rheumatic Drug (DMARD) Therapy -2011

98. Sub-Investigator Protocol H9B MC BCDP, A Phase IIIb, Multicenter, Open-Label Study to Evaluate the Long-Term Safety and Efficacy Of XXXX in Patients with Rheumatoid Arthritis (RA) -2011

99. Sub-Investigator Protocol H9B MC BCDV, A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate The Efficacy and Safety of XXXX in Patients with Moderate to Severe Rheumatoid Arthritis (RA) who had Inadequate Response To one or more TNF-α Inhibitors -2011

100. Principal Investigator 10-OA-004, An Open Label, Safety ExtensionStudy of Repeat Dosing with XXXX in Subjects with Osteoarthritis (OA) of the Knee

101. Sub-Investigator Protocol 1218.75, A Phase IIIb, 24-week, randomized, placebo-controlled, double-blinded, efficacy andsafety study of XXXX in Black/African American patientswith type 2 diabetes with a MTT sub-study

102. Sub-Investigator Protocol TZP-101-CL-P008, A Multicenter,Randomized, Double-Blind, Placebo-Controlled Study to Evaluatethe Efficacy and Safety of Intravenous (IV) XXXX Administered Post-Operatively to Accelerate Recovery of Gastrointestinal (GI)Motility inSubjects Who Have Undergone Partial Bowel Resection

103. Sub-Investigator Protocol RAS-RLS, Safety and Efficacy of XXXX in Restless Leg Syndrome

104. Sub-Investigator Protocol AS001, A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled study to evaluateefficacy and safety of XXXX in subjects with active axialspondyloarthritis (axial spa)

105. Sub-Investigator Protocol SMR/0211OBD-1003, A Multicenter,Randomized, Placebo-controlled, Double-blinded Study of theEfficacy and Safety of XXXX in Subjects with Opioid-inducedBowel Dysfuntion

106. Sub-Investigator Protocol RA0056, A Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study with an Active Comparator to Evaluate the Efficacy and Safety of XXXX Administered Subcutaneously for 12 Weeks to Subjects with Active Rheumatoid Arthritis Having Previously Failed TNF-Blocker Therapy

16

107. Sub-Investigator Protocol RA0057, A Phase II Multi-Center, Open-Label, Follow-Up Study to Assess the Long-Term Safety and Efficacy of XXXX Administered Subcutaneously to Subjects With Active Rheumatoid Arthritis who Completed Study RA0056

108. Sub-Investigator Protocol TGC-09201, A Phase II Study to Determine the Efficacy and Safety of XXXX Expressing XXXX in Patients with Grade 3 Chronic Degenerative JointDisease of the Knee

109. Sub-Investigator Protocol CAIN457F2208, A multicenter, 12 week, randomized, double-blind, placebo-controlled biomarker study of XXXX in rheumatoid arthritis patients followed by an open label Extension

110. Principal Investigator Protocol D4300C00004, A Phase IIb, Multi-Centre, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy and Safety of XXXX Compared with XXXX in Patients with Active Rheumatoid Arthritis

111. Principal Investigator Protocol D4300C00005, A Long-term Extension Study to Assess the Safety and Efficacy of XXXX in the Treatment of Rheumatoid Arthritis

112. Sub-Investigator CACZ885M2301: A randomized, double-blind, placebo-controlled, event-driven trial of quarterly subcutaneous XXXX in the prevention of recurrent cardiovascular events among stable post-myocardial infarction patients with elevated hsCRP

113. Sub-Investigator MKC-TI-175, A phase III, Multicenter, Double-blind, Placebo-controlled, Randomized, Clinical Trial Evaluating the Efficacy and Safety of XXXX/ XXXX Insulin Inhalation Power Versus XXXX Inhalation Powder (Placebo) in Insulin Naive Subjects With Type 2 Diabetes Mellitus Poorly ;Controlled wit Oral Antidiabetic Agents Over a 24 Week Treatment Period

114. Principal Investigator IAP309: A Multicenter, Randomized, Open-Label, Parallel-Group Trial to Compare the Efficacy and Safety of the XXXX PCA System/15mcg to Intravenous Patient-Controlled Analgesia with Morphine for the Treatment of Acute Post-Operative Pain

115. Sub-Investigator SAS115359: A Safety and Efficacy Study of Inhaled XXXX/XXXX versus Inhaled XXXX in the Treatment of Adolescent and Adult Subjects with Asthma

116. Sub-Investigator HZC113782: A Clinical Outcomes Study to compare the effect of XXXX/XXXX 100/25mcg with placebo on Survival in Subjects with moderate Chronic Obstructive Pulmonary Disease (COPD) and a history of or at increased risk for cardiovascular disease

117. Principal Investigator AUX-CC-870: A Phase IIa, Open-Label, Dose-Ranging Study of the Safety and Effectiveness of XXXX for the treatment of Adhesive Capsulitis of the Shoulder

17

118. Sub-Investigator CC-10004-AS-001: A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of XXXX in the Treatment of Active Ankyloosing Spondylitis

119. Sub-Investigator 27018966IBS3001: A Randomized, Double-blind, Placebo-controlled, Phase III Study to Evaluate the Efficacy, Safety and Tolerability of XXXX in the Treatment of Patient With Diarrhea-Predominant Irritable Bowel Syndrome

120. Principal Investigator HYD3002: A Multicenter, Randomized, Double-blind, Placebo-controlled Study With an Open-label Run-in to Assess the Efficacy and Safety of XXXX Tablets 20 to 120 mg Once-daily in Subjects with Moderate to Severe Chronic Low BackPain

121. Principal Investigator ONU3704: A Randomized, Double-blind, Double-dummy, Placebo-controlled, Active-controlled, Parallel-group, Multicenter Trial of XXXX/XXXXControlled-release Tablets (OXN) to Assess the Analgesic Efficacy (Compared to Placebo) and the Management of Opioid-induced Constipation (Compared to XXXX Controlled-release Tablets (OXY) in Opioid-experienced Subjects with Uncontrolled Moderate to Severe Chronic Low Back Pain and a History of Opioid-induced Constipation who Require Around-the-clock Opioid Therapy

122. Principal Investigator X052160: A Phase II poof-of-concept study of XXXX in active inflammatory, erosive osteoarthritis of the hand

123. Sub-Investigator CC-10004-PSA-004: A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy and Safety Study of Two Doses of XXXXXXXXXX (XX-XXXXX) in Subjects with Active Psoriatic Arthritis and a Qualifying Psoriasis Lesion

124. Sub-Investigator 5945-SOIC-12-05: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study to Evaluate the Long-term Safety and Tolerability of XX-XXXX for the Treatment of Opioid-induced Constipation in Adults Taking Opioid Therapy for Chronic Non-Cancer Pain

125. Sub-Investigator GRT-MD-101: A Randomized, Double-Blind, Placebo- and Active-Controlled Study to Evaluate the Safety and Efficacy of XXXXXXX in Patients with Moderate to Severe Chronic Pain Due to Osteoarthritis of the Knee

126. Sub-Investigator 27018966IBS3001: A Randomized, Double-blind, Placebo-controlled, Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of XXX-XXXXXXXX in the Treatment of Patients With Diarrhea-Predominant Irritable Bowel Syndrome

127. Sub-Investigator Protocol H9B-MC-BCDT: A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous XXXXXXXXX in Patients with Systemic Lupus Erythematosus (SLE)

18

128. Sub-Investigator Protocol H9B-MC-BCDX: A Phase IIIb, Multicenter, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of Subcutaneous XXXXXXXXX in Patients with Systemic Lupus Erythematosus (SLE) ( ILLUMINATE-X)

129. Principal Investigator I1Q-MC-JDDE: a Phase II randomized Study to Investigate the Efficacy and Safety of XXXXXXXXX Versus Placebo in Older Patients Undergoing Elective Total Hip Arthroplasty (eTHA)

130. Sub-Investigator Protocol 71040701: A Double-Blind, Randomized, Placebo-Controlled,Parallel Group, Multi-Site Study to Evaluate the Clinical Equivalence of XXXXXXXXXX XXXXXX 1% Gel (Anchen Pharmaceuticals, Inc.) with Voltaren® Gel (diclofenac sodium topical gel) 1% (Novartis) in Patients with Osteoarthritis of the Knee

131. Sub-Investigator B0151006: A double-blind, randomized, placebo-controlled, multicenter, dose-ranging study to evaluate the efficacy and safety of XX-XXXXXXXX in subjects with systemic lupus erythematosus (SLE)

132. Sub-Investigator 35GA1203: A Multi-center, Randomized, Double-Blind, Saline-Controlled Study of a Single Injection of Durolane® versus a Single Injection of Phosphate Buffered Saline (PBS) to Treat Pain Associated with Osteoarthritis of the Knee

133. Sub-Investigator BA058-05-003:A Randomized, Double-blind, Placebo-controlled, Comparative Phase III Multicenter Study to Evaluate the Safety and Efficacy of XXXXXfor Injection for Prevention of Fracture in Ambulatory Postmenopausal Women with Severe Osteoporosis and at Risk of Fracture

134. Sub-Investigator BC28027: A Phase IIIb Study To Evaluate the Potential of XXXXXXXXXXX to Reduce Cardiovascular Risk in Patients with Stable Cardiovascular Disease and Glucose Abnormalities

135. Sub-Investigator M5I02: Safety and Immunogenicity of XXXX-XXXXXX (XXXX and XXXX) Compared to DAPTACEL® (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed) + IPOL® (Poliovirus Vaccine Inactivated) as the 5th Dose inChildren 4 to 6 Years of Age

136. Principal Investigator X052161: An Open-label Safety Extension Study of XXXXXXXXXXX in Active Inflammatory, Erosive Osteoarthritis of the Hand (Extension of Study X052160)

137. Principal Investigator X052162: A Phase II Proof-of-concept Study of XXXXXXXXXXX in Subjects with Inflammatory Erosive Osteoarthritis of the Hand, X052162

138. Principal Investigator ZAL160-LSR-201: A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of XXXX in Subjects with Neuropathic Pain from Lumbosacral Radiculopathy

19

139. Sub-Investigator Gel/1133: A Multi-Center, Randomized, Double-Blind, Phosphate Buffered Saline-Controlled Study to Evaluate Effectiveness and Safety of a Single Intra-Articular Injection of XXX-XXX® for the Treatment of Osteoarthritis of the Knee with Open-Label Safety Extension

140. Principal Investigator 6603/1131: A Multicenter, Randomized, Double-blind, Controlled,Comparative Study of XX-XXXX in Patients with Lumbar Disc Herniation (Phase III)

141. Sub-Investigator TGC-B106727: Long-Term Safety Follow-Up of Study Subjects Who Were Previously Enrolled in a XXXXXXXXXX Clinical Trial and Were Administered XXXXXXXXXX-X

142. Sub-Investigator 5945-SOIC-12-04 : A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study to Evaluate the Efficacy and Safety of XX-XXXX for the Treatment of Opioid-induced Constipation in Adults Taking Opioid Therapy for Chronic Non-Cancer Pain

143. Principal Investigator FX006-2014-006: A Double-Blind, Randomized, Parallel Group, Dose-Ranging Study to Assess the Safety and Efficacy of XXXXX for the Treatment of Pain in Patients with Osteoarthritis of the Knee

144. Principal Investigator SKK-1132: A Multicenter, Open-label Study of XXX in Patients with Lumbar Disc Herniation (Phase III)

145. Principal Investigator AV01.2015-0863: A Double-Blind, Randomized, Study of the Effectiveness and Safety of XXX for the Treatment of Osteoarthritis of the Knee

146. Sub-Investigator M15-555: A Phase 3, Randomized, Double-Blind Study Comparing XXX Monotherapy to Methotrexate (MTX) in Subjects with Moderately to Severely Active Rheumatoid Arthritis with Inadequate Response to MTX

147. Sub-Investigator M13-542: A Phase 3, Randomized, Double-Blind Study Comparing XXX to Placebo on Stable Conventional Synthetic Disease-Modifying Anti-Rheumatic (csDMARDs) in Subjects with Moderately to Severely Active Rheumatoid Arthritis with Inadequate Response or Intolerance to Biologic DMARDs (bDMARDs)

148. Sub-Investigator ALX0061-C204: A Phase II Multicenter, Randomized, Double-blind, Placebo-controlled, dose-range Finding Study to Evaluate the Safety and Efficacy of XXX Administered Subcutaneously in Subjects with Moderate to Severe Active SystemicLupus Erythematosus

149. Principal Investigator 205180: A Phase IIa, Double-Blind, Mechanistic Study of XXX in Combination with Methotrexate Therapy in Subjects with Active Rheumatoid Arthritis Despite Treatment with DMARDs

150. Principal Investigator 166770-005CL: A Randomized, Double Dummy, Parallel Arm, Placebo- And Active Controlled, Double-Blind, Study of the Safety and Efficacy of XXX

20

as Monotherapy in Adults with Moderate-to-Severe Knee Pain Due to Osteoarthritis who are Inappropriate for Oral Non-Steroidal Anti-Inflammatory Therapy.

151. A Multicenter, Randomized, Double-blind, Controlled, Comparative Study of XXX in Patients with Lumbar Disc Herniation (Phase III)

152. A Multi-Center, Randomized, Double-Blind, Phosphate Buffered Saline-Controlled Study to Evaluate Effectiveness and Safety of a Single Intra-Articular Injection of Gel-One® for the Treatment of Osteoarthritis of the Knee With Open-Label Safety Extension - 2015

153. Seikagaku CorporationA Multicenter, Open-label Study of XXX in Patients With Lumbar Disc Herniation (Phase III) – 2015

154. Actavis Inc.A Double-Blind, Randomized, Study of the Effectiveness and Safety of XXX for Treatment of Osteoarthritis of the Knee - 2015

155. A Randomized, Double-blind, Placebo-controlled, Event Driven Trial of Quarterly Subcutaneous XXX in the Prevention of Recurrent Cardiovascular Events Among Stable Post-Myocardial Infarction Patients With Elevated hsCRP – 2015

156 A Phase 3, Randomized, Double-Blind Study Comparing XXX to Placebo on Stable Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) in Subjects With Moderately to Severely Active Rheumatoid Arthritis With Inadequate Response or Intolerance to Biologic DMARDs (bDMARDs) – 2016

Patents and Intellectual Property

Item/Technology Proprietary Patent(s) Key Dates

“Talon” Trademark Application Notice of Allowance 08/19/2003

Talon® Compression Hip Screw + Additional Claims+ Additional Claims+ Foreign Claims+ Foreign Application

Patent Number 5,976,139Patent Number 6,183,474 B1Patent Number 6,695,844Australia Patent No. 757037PCT/US00/01709

11/02/199902/06/20012/24/20045/15/2003-NA-

Talon® Intramedullary Hip Nail

+ Foreign Application

Patent Number 6,443,954

PCT/US02/15245

09/03/2002

07/25/2002

21

Talon® Intramedullary Hip Nail w/ Bifurcated Lock

+ Foreign Application

Patent Number 6,648,889

PCT/US02/33614

11/18/2003

11/06/2002

Talon® Intramedullary Nail Patent Number 6,488,684 12/03/2002

Endoscopic Carpal Tunnel Release Patent Number 5,649,946 07/22/1997

Talon® Spine Cage Patent Number 6,447,546 09/10/2002

Spinal Implant (Talon® Artificial Disc)Anchor-Plate with Tang Fixation

Application No. 29/192,496 10/24/2003

Interfragmentary Compression Screw Patent Number 5,827,285 10/27/1998

Surgical Anchor Patent Number 5,849,004 12/15/1998

Arthroplasty Joint Assembly+ Additional Claims

Patent Number 5,984,970Patent Number 6,475,242

11/16/199911/05/2002

Acetabular Shell with Tang FixationApplication No. 29/175,406

Notice of Allowance11/07/2003

Femoral Neck Compression System with Ortho-Biologic Material Delivery Capacity

Application No. 10/766,666 1/27/2004

Orthopedic Barrel Washer for Compression of Bone Fragments Application No. 60/554,780 3/19/2004

U.S. Patents Issued

Name: Surgical AnchorNumber: 5,849,004Issue Date: 12/15/98 Name: Carpal Tunnel Medical InstrumentNumber: 5,649,946Issue Date: 7/22/97 Name: MultipieceInterfragmentary Fixation AssemblyNumber: 5,827,285Issue Date: 10/27/98

22

Name: Talon Compression Hip ScrewNumber: 5,976,139Issue Date: 11/2/99 Name: +Additional ClaimsNumber: 6,183,474b1Issue Date: 2/6/01 Name: +Additional ClaimsNumber: 6,695,844Issue Date: 2/24/04 Name: +Foreign ClaimsNumber: Australia Patent No. 757037Issue Date: 5/15/03 Name: Foreign ApplicationNumber: PCT/USOO /01709Issue Date: N/A

Name: Arthroplasty Joint AssemblyNumber: 5,984,9702Issue Date: 11/16/99 Name: Intramedullary Hip Nail w/Bifurcated LockNumber: 6,648,889Issue Date: 11/18/03 Name: +Foreign ApplicationNumber: PCT/USOO/2/33614Issue Date: 11/6/02 Name: Femoral Nail Intramedullary SystemNumber: 6,443,954Issue Date: 9/03/02

Name: Foreign ApplicationNumber: PCT/USO2/15245Issue Date: 7/25/02

Name: Apparatus and Method for Fusing Opposing Spinal VertebraeNumber: 6,447,546Issue Date: 9/10/02 Name: Arthroplasty Joint AssemblyNumber: 6,475,242Issue Date: 11/05/02

23

Name: Intramedullary NailNumber: 6,488,684Issue Date: 12/03/02

Publications and Papers Presented at National Meetings

1. Bramlet, D.G.; Browning, R.A. and Myers, J.H. "Examination of Blood PressureChanges Following the Destruction of Ascending Serotonergic Neurons in SpontaneouslyHypertensive Rats" Abstract: Society for Neuroscience 5:330 (1979)

2. Browning, R.A., Bramlet, D.G. Et. al. "Failure to Produce Blood Pressure ChangesFollowing Pharmacological or Surgical Depletion of Brain Serotonin in theSpontaneously Hypertensive Rat" Clinical and Experimental Hypertension 3(5), 953-973, (1981)

3. Bramlet, D.G., Pellegrini, V.D., Jr. and Burton, R.I. "Long Term Follow-up of LigamentReconstruction with Tendon Interposition Arthroplasty (LRTI) For Basal JointOsteoarthritis of the Thumb" Presented: American Academy of Orthopaedic Surgeons,Las Vegas, NV February 1989

4. Tomaino, M.M., Pelligrini, V.D., Jr, Bramlet, D.G. and Burton, R.I. "Arthroplasty of theThumb Basal Joint: Long Term Follow-up of Ligament Reconstruction with TendonInterposition" Presented American Society for Surgery of the Hand, 47th AnnualMeeting, Phoenix AZ, (November 1992)

5. Co-Chairman, Wright Medical Technology, Inc. Seminar on Reconstructive Surgery ofthe Upper Extremity, St. Pete Beach, FL (1998)

6. Bramlet, Dale G., “Reconstruction of the MCP Joint in Rheumatoid Arthritis” Presented:Wright Medical Technology, Inc. Seminar on Reconstructive Surgery of the UpperExtremity, St. Pete Beach, FL (1998)

7. Bramlet, Dale G., “Ligamentous Reconstruction of the Hand and Wrist” Presented:Wright Medical Technology, Inc. Seminar on Reconstructive Surgery of the UpperExtremity, St. Pete Beach, FL (1998)

8. Bramlet, Dale G., “Reconstruction of the Arthritic Carpus, Limited Wrist Fusion”Presented: Wright Medical Technology, Inc. Seminar on Reconstructive Surgery of theUpper Extremity, St. Pete Beach, FL (1998)

9. Bramlet, Dale G., “Surgical Exposures/Challenging Cases“ Presented: Wright MedicalTechnology, Inc. Seminar on Reconstructive Surgery of the Upper Extremity, St. PeteBeach, FL (1998)

10. Bramlet, Dale G.; Weiss-Lessard, Susan OTR/L CHT; Lastayo, Paul, MPT CHT;

24

Mills, Amy OT/L “Splinting, The First CMC Joint, An Objective, Subjective andRadiographic Assessment. Best Scientific Paper, 22nd Annual Meeting, AmericanSociety of Hand Therapists, Orlando, FL (September 1999)

11. Bramlet, Dale G. Contributing Author for two chapters “Arthritis” and “Fractures” inbook “Hand Rehabilitation - A Quick Reference Guide and Review” Mosby 1999 Weiss-Lessard, Susan OTR/L CHT

12. Bramlet, Dale G; Presentation at Strategic Implications and Organon/Sanofi Symposium:FDA Approval of Medical Devices: The Talon Hip compression Screw, San Diego, CA(November 5, 2000)

13. Bramlet, Dale G; Presentation at Strategic Implications and Organon/Sanofi Symposium:FDA Rationale for Venography in Clinical Research Studies Related to Deep VeinThrombosis, San Diego, CA (November 5, 2000)

14. Bramlet, Dale G; Poster Presentation at Staten Island University Hospital AnnualSymposium: Avoiding Complications & Improving Outcomes in Orthopaedic Surgery:“Clinical Analysis of the Talon Hip Compression Screw in Intertrochanteric HipFractures” St. Thomas, US Virgin Islands (December 4-6, 2001)

15. Bramlet, Dale G; Poster Presentation at Staten Island University Hospital AnnualSymposium: Avoiding Complications & Improving Outcomes in Orthopaedic Surgery:“Biomechanical Testing of the Talon Hip Compression Screw in Intertrochanteric HipFractures” St. Thomas, US Virgin Islands (December 4-6, 2001)

16. Prospective Analysis of Neoprene and Thermoplastic Splinting for the FirstCarpometacarpal Joint, Bramlet, Dale G.; Weiss, Susan OTR/L CHT; LaStayo, Paul,American Association for Hand Surgery, Controversies in Hand Surgery, Cancun,Mexico, (January 2002)

17. Oral Presentation: Torsional Testing of the Talon Hip Compression Screw, SIROT 2002XXII World Congress, San Diego, (August 2002)

18. Oral Presentation: Biomechanical Evaluation of the Talon Hip Compression Screw,SIROT 2002 XXII World Congress, San Diego, (August 2002)

19. Poster Presentation: Clinical Analysis of the Talon Hip Compression Screw, SICOT 2002XXII World Congress, San Diego, (August 2002)

20. Abstract accepted for Oral presentation: Phase I/II Evaluation of a Thrombin-RelatedPeptide for Acceleration of Distal Radius Fracture Healing; Levine, Benjamin P., M.D.,Ward, W. Alan, M.D., Bramlet, Dale G.,M.D., Ladd, Amy L., M.D. ASSH 57th AnnualMeeting, Phoenix, AZ (October 2-5, 2002)

21. Presentation at Staten Island University Hospital Annual Symposium: Complications ofIntertrochanteric Hip Fractures, St. Thomas, US Virgin Islands (December 2002)

25

22. Presentation at Staten Island University Hospital Annual Symposium: BiomechanicalAnalysis of Proximal Femoral Fractures, St. Thomas, US Virgin Islands (December 2002)

23. Use of the Talon Hip Compression Screw in Intertrochanteric fractures of the hip. AuthorDale G. Bramlet: Clinical Orthopaedic and Related Research. (August 2004)

24. Biomechanical Evaluation of a New Type Hip Compression Screw With RetractableTalons. Journal of Orthopedic Trauma (October 2003)

25. Course Chairman DVT Prophylaxis in Total Joints. Biomechanical and Outcomes of HipFractures. Marco Island, Fla. Make a Difference A Difference Updates in OrthopaedicSurgery and Musculoskeletal Therapeutics. (March 25-28, 2004)

26. Presentation: Talon Hip Compression Screw in Intertrochanteric Fractures of the Hip.Western Orthopaedic Association. Seascape Resort, Monterey Bay, California (May 13-15, 2005)

27. Publication in a special Journal of Bone and Joint Surgery. “Thrombin Peptide TP508Stimulates Cellular Events Leading to Angiogenesis, Revascularization, and Repair ofDermal and Musculoskeletal Tissues”

28. Presentation: Venous Thromboembolic Disease in Total Joints. Make a DifferenceConference 2nd Annual March 17-20th, 2005, Marco Island, Fl

29. Presentations: Advances in Hip Fractures Treatment and Orthobio-logics, 3rd AnnualMake a Difference Conference, April 20-23rd, 2006, Marco Island, Fl.

30. Thrombin peptide TP508 stimulates cellular events leading to angiogenesis,revascularization, and repair of dermal and musculoskeletal tissues.Ryaby, J.T., Sheller,M.R., Levine, B.P., Bramlet, D.G., Ladd, A.L., Carney, D.H.J Bone Joint Surg Am 2006Nov

31. Presentation: MAGI WEST Clinical Research Annual Meeting Oct 27 – 30, 2013. LasVegas Nevada: Panelist: Contributing to Efficiencies in the IRB Process

32. Presentation: MAGI EAST Clinical Research Annual Meeting May 4 th – 7th, 2014,Philadelphia, PA: Source Document Preparation and Quality Control

33. Section Chair: MAGI EAST Clinical Research Annual Meeting May 4 th – 7th, 2014,Philadelphia, PA: The Study Participant Experience

34. Presentation: MAGI WEST Clinical Research Annual Meeting, Nov 10 th,2014 SanFrancisco, CA Metrics for Site Management and Business Development

35. Section Chair: MAGI WEST Clinical Research Annual Meeting, Nov 11th,2014 SanFrancisco, CA, Panel Discussion: Site Operations “Challenges: Do you Really Expect Usto do This?”

26

36. MAGI EAST, Clinical Research Meeting, May 13th, 2015, Arlington Virginia, SiteChallenges: Do you really expect us to do this? Panel Discussion

37. MAGI WEST Clinical Research Meeting, October 14th, 2015, Dan Diego, Calif,Research Site Toolbox – 1 hour presentation

38. Invited MAGI West clinical Research Meeting, October 24th, 20156, Las Vegas Nevada,E586 Modernizing Your Site

39. MAGI EAST Clinical Research Meeting, May 21 – 24, 2017, Philadelphia,Pennsylvania , Are you Hearing us? Are we hearing you?

40. Academy of Physician’s in Clinical Research Meeting, October 20 – 22, 2017, Orlando,Fl Site / Sponsor Collaborations: Solutions to Key Issues

Presentations at Regional Meetings

1. Major Limb Salvage: Revascularization in Children, 26th Annual Dillehunt MemorialLecture, Shriners’ Hospital for Crippled Children, Portland OR -April 1986

2. Allografting for Revision Total Hip Arthroplasty, North Pacific Orthopaedic Society,Tacoma, WA -May 1986

3. Genu Recurvatum, 27th Annual Dillehunt Memorial Lecture, Shriners Hospital forCrippled Children, Portland, OR -April 1987

4. Combined Septic Arthritis and Osteomyelitis of the Ankle: A Case Report, 27th AnnualDillehunt Memorial Lecture, Shriners Hospital for Crippled Children, Portland, OR-April 1987

5. Muscle Strength Following Open Reduction and Internal Fixation of AcetabularFractures, Second Annual Orthopaedic Scientific Session, Oregon Health SciencesUniversity, Portland, OR -June 1987

6. Long Term Follow-up of Ligament Reconstruction with Tendon Interposition (LRTI)Arthroplasty of Basal Joint Arthritis of the Thumb, Annual Hand Fellow Conference,Rochester, NY -May 1988

7. Long Term Follow-up of Ligament Reconstruction with Tendon Interposition (LRTI)Arthroplasty of Basal Joint Arthritis of the Thumb, American Academy of OrthopaedicSurgeons, Las Vegas, NV -February 1989

8. Decision Making in Single Digit Injuries of the Hand, Annual Fellow Hand Conference,

27

Rochester, NY -April 1989

9. Pathological Calcification of the Hand, Annual Fellow Hand Conference, Rochester, NY-April 1991

10. APR Total Hip Replacement, Regional Tech Course, St. Petersburg Beach FL March1992

11. Four Corner Arthrodesis of the Wrist, Annual Hand Fellow Hand Conference, Rochester,NY -May 1992

12. Mini-Fragment Set, AO/ASIF, Operating Room Nurses Personnel Course, ClearwaterBeach, FL -October 1992

13. Limited Intercarpal Arthrodesis - A Retrospective Review Florida Hand Society, Orlando,FL May 1995 Co-Author Susan Weiss-Lessard, ORT/L

14. Innovations in Carpal Tunnel Surgery - Fiftieth Annual Florida Workers' CompensationEducational Conference -September 19, 1995

15. Vascularized Bone Grafting for Treatment of Avascular Necrosis of the Femoral Head -Florida Orthopaedic Society, South Palm Beach, FL May 1996 Co-Authors Norman R.Harris, M.D. and Jorge Rodriguez, M.D.

16. Outcomes of Carpal Tunnel Surgery, Annual Hand Fellow Hand Conference, Rochester,NY May 1996 Co-Authors Dr. Scott Raub and Susan Weiss-Lessard

17. Treatment of Refractory Sesamoiditis: An Approach to the Painful Thumb, Florida HandSociety -May 1997

18. Treatment of Refractory Sesamoiditis: An Approach to the Painful Thumb, SMA 91stAnnual Scientific Assembly, Charlotte, NC, -November 1997

19. Metacarpophalangeal Joint Arthroplasty: A Critical Review, SMA 91st Annual ScientificAssembly, Charlotte, NC, -November 1997

20. LRTI Arthroplasty as Treatment for Basal Joint Osteoarthritis, Florida Hand Society-May 1998

21. Complications in ORIF Intertrocheal Fracture of the Hip-Introduction of TalonCompression Hip Screw System Bayfront Medical Center -November 11, 1999

22. Use of Pain Pumps as an Adjunctive Therapy for LRTI Arthroplasty of the Thumb Joint,Florida Hand Society, -May 5, 2000

23. Biomechanical Evaluation of a Hip Screw System with Retractable Tangs, FloridaOrthopaedic Society, -June 2, 2000

24. Panel member Florida Orthopaedic Society, Difficult Case Review Osteoarthritis of the

28

Hip and Knee, June 2, 200025. Presentation: Complications of Intertrochanteric Fractures of the Hip, Tampa, FL

-September 14, 2000

26. Presentation at Jacksonville Orthopaedic Society: Complications of IntertrochantericFractures of the Hip, Jacksonville, FL, -September 21, 2000

27. Presentation at Workers Compensation Conference: Cumulative Trauma Disorders in theWorkers Compensation Patient, Tampa, FL -October 27, 2000

28. Presentation: Complications of Intertrochanteric Fractures of the Hip, Port Richey, FL-November 1, 2000

29. Presentation: Complications of Intertrochanteric Fractures of the Hip, Clearwater, FL-November 8, 2000

30. Presentation: Complications of Intertrochanteric Fractures of the Hip, Fort Meyers, FL-November 14, 2000

31. Presentation: Complications of Intertrochanteric Fractures of the Hip, St. Petersburg, FLNovember 30, 2000

32. Presentation: Complications of Intertrochanteric Fractures of the Hip, Sarasota, FL-December 7, 2000

33. Presentation: Complications of Intertrochanteric Fractures of the Hip, Naples, FL-January 18, 2001

34. Presentation: Complications of Intertrochanteric Fractures of the Hip, Lakeland, FL-February 20, 2001

35. Presentation: Complications of Intertrochanteric Fractures of the Hip, Orlando, FL-March 13, 2001

36. Presentation: Efficacy of Pain Pumps in LRTI Arthroplasty-A prospective Study. FloridaHand Society, -May 18, 2001

37. Presentation: Complications of Intertrochanteric Fractures of the Hip, Scottsdale, AZ-August 7, 2001

38. Presentation: Complications of Intertrochanteric Fractures of the Hip,MedProOrthopaedics, Phoenix Orthopaedic Residency Program Grand RoundsConference, Phoenix, AZ -August 8, 2001

39. Presentation: Complications of Intertrochanteric Fractures of the Hip, Bismarck, NDAugust 14, 2001

40. Presentation: Complications of Intertrochanteric Fractures of the Hip, Naples, FL

29

-September 6, 2001

41. Presentation: Complications of Intertrochanteric Fractures of the Hip, Tampa, FL-October 2, 2001

42. Presentation: Complications of Intertrochanteric Fractures of the Hip, Bismarck, ND-October 8, 2001

43. Presentation: Complications of Intertrochanteric Fractures of the Hip, San Diego, CA-October 17, 2001

44. Presentation: Complications of Intertrochanteric Fractures of the Hip, Jacksonville, FL-November 15, 2001

45. Presentation: Complications of Intertrochanteric Fractures of the Hip, Las Vegas, NV-November 20, 2001

46. Presentation: Biomechanics of Intertrochanteric Fractures of the Hip, Fort Lauderdale, FL-February 21, 2002

47. Presentation: Biomechanics of Intertrochanteric Fractures of the Hip, Sarasota, FL-March 20, 2002

48. Presentation: Treatment of Complications of Intertrochanteric Fractures of the Hip,Mount Vernon, IL -June 24, 2002

49. Presentation: Biomechanics of Intertrochanteric Fractures of the Hip, Milwaukee, WI-June 25, 2002

50. Strategies in Treatment of Intertrochanteric Fractures of the Hip, Rounds at Los AngelesCounty, Martin Luther King Hospital, -September 4, 2002

51. Presentation: Treatment of Complications of Intertrochanteric Fractures of the Hip,Oklahoma City, OK -September 17, 2002

52. Grand Rounds Presentation at Mount Sinai Medical Center, New York, NY,Complications of Intertrochanteric Hip Fractures; Biomechanical Analysis of ProximalFemoral Fractures -January 8, 2003

53. Grand Rounds Presentation at Winthrop University Hospital, Mineola, NY Complicationsof Intertrochanteric Hip Fractures; Biomechanical Analysis of Proximal FemoralFractures -January 10, 2003

54. Grand Rounds Presentation at Orlando Regional Hospital, Orlando, Fl Complications ofIntertrochanteric Hip Fractures; Biochemical Analysis of Proximal Femoral Fractures-April 18, 2003

30

55. Grand Rounds Presentation at The New York Hospital Medical Center of Queens,Flushing NY Current Management of Hip Fracture -May 21, 2003

56. Presentation at Workers Compensation Medical Seminar entitled “Worker’sCompensation Injuries, Medical and Adjuster Case Management” Cumulative TraumaDisorders in the Workers Compensation Patient, Tampa, Fl -June 20, 2003

57. Special Medical Feature, M.D. News, Tampa Bay Edition October 2003 Cover Article“Talon Technology- Restoring Mobility to Patients”

58. Presentation: Orthopaedic and Trauma Seminar Biochemical Evaluation ofIntertrochanteric and Subtrochanteric Hip Fractures Minneapolis, MN -November 14,2003

59. Presentation: Florida Orthopedic Society Ocean Reef Club Key Largo, FL ScaphoidLunate Disassociation -May 20, 2004

60. Make A Difference Seminar in Marco Island Marriott Resort Marco Island, Fl Co-Chairman and Speaker on DVT Prophylaxis in Total Joint Replacement. -March 25-28,2004.

61. Grand Rounds Vanderbilt University Medical Center. Complications of Hip FractureSurgery Nashville, TN -June 3, 2005.

62. Presentation-ODI Hip Talon Technology, Use, Complications and Results- UniversityKansas, Wichita, KS -June 26, 2006

63. Grand Rounds, University of South Florida, Tampa, The Arthritic Carpus, -December18th, 2009

64. Grand Rounds, University of South Florida, Tampa, Complications of Hip FractureSurgery, -January 29th, 2010

Presentations

1. Management of Acetabular Fractures - A Review of Cases, Department of OrthopaedicSurgery, Oregon Health Sciences University, Portland, OR -February 1985

2. Proximal Tibial Osteotomy, Department of Orthopaedic Surgery, Oregon Health SciencesUniversity, Portland, OR -May 1985

3. Management of Pediatric Orthopaedic Trauma, Department of Family Practice, OregonHealth Sciences, Portland, OR -June 1985

4. Infections in Orthopaedic Surgery, Department of Orthopaedic Surgery, Oregon Health

31

Sciences University, Portland, OR -August 1985

5. Revision Total Hip Arthroplasty, Department of Nuclear Medicine, VeteransAdministration Medical Center, Portland, OR -October 1985

6. Bone Allografting in Hip Arthroplasty, Department of Orthopaedic Surgery, OregonHealth Sciences University, Portland OR -April 1986

7. Genu Recurvatum, Department of Orthopaedic Surgery, Oregon Health SciencesUniversity, Portland,- OR June 1986

8. Total Hip Arthroplasty, Department of Radiology, Oregon Health Sciences University,Portland, OR -January 1987

9. Steffe Plate Arthrodesis of the Spine, Department of Orthopaedic Surgery, Oregon HealthServices University, Portland, OR -April 1987

10. Metacarpal and Phalangeal Fractures, Department of Orthopaedic Surgery, University ofRochester Medical Center, Orthopaedic and Plastic Surgery hand Conference, Rochester,NY -July 1987

11. Small Joint Dislocations in the Hand, Department of Orthopaedic Surgery, University ofRochester Medical Center, Orthopaedic and Plastic Surgery hand Conference, Rochester,NY -August 1987

12. Scaphoid Fractures, Department of Orthopaedic Surgery, University of RochesterMedical Center, Orthopaedic and Plastic Surgery Hand Conference, Rochester, NY-August 1987

13. Flexor Tendon Injury and Repair, Department of Orthopaedic Surgery, University ofRochester Medical Center, Orthopaedic and Plastic Surgery Hand Conference, Rochester,NY -November 1987

14. Carpal Kinematic and Instability, Department of Orthopaedic Surgery, University ofRochester Medical Center, Orthopaedic and Plastic Surgery Hand Conference, Rochester,NY -December 1987

15. The Arthritic Carpus, Department of Orthopaedic Surgery, University of RochesterMedical Center, Orthopaedic and Plastic Surgery hand Conference, Rochester, NY -January 1988

16. Kienbock's Disease, Department of Orthopaedic Surgery, University of RochesterMedical Center, Hand Conference, Rochester, NY -February 1988.

17. The Arthritic Carpus, Department of Orthopedics, University of Rochester MedicalCenter, Hand Conference, Rochester, NY -March 1988

32

International Presentations

1. 3rd International Conference Biomechanics of the Lower Limb in Health, Disease andRehabilitation. University of Salford, Manchester, England -September 5th thruSeptember 7th, 2005

33